For MM patients who receive anti-BCMA CAR-T for the first time, CAR-T cell reinfusion can be performed based on the expression of BCMA antigen when the patients do not respond to CAR-T or relapse after remission [120-122]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.